Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kezar Life Sciences (KZR) Assets Average (2021 - 2025)

Kezar Life Sciences' Assets Average history spans 5 years, with the latest figure at $135.0 million for Q1 2025.

  • For Q1 2025, Assets Average fell 35.78% year-over-year to $135.0 million; the TTM value through Mar 2025 reached $135.0 million, down 35.78%, while the annual FY2024 figure was $183.0 million, 29.74% down from the prior year.
  • Assets Average for Q1 2025 was $135.0 million at Kezar Life Sciences, down from $154.4 million in the prior quarter.
  • Across five years, Assets Average topped out at $311.1 million in Q3 2022 and bottomed at $135.0 million in Q1 2025.
  • The 5-year median for Assets Average is $222.5 million (2022), against an average of $219.2 million.
  • The largest annual shift saw Assets Average soared 129.99% in 2022 before it crashed 35.78% in 2025.
  • A 5-year view of Assets Average shows it stood at $174.4 million in 2021, then soared by 73.25% to $302.2 million in 2022, then decreased by 22.14% to $235.3 million in 2023, then crashed by 34.38% to $154.4 million in 2024, then fell by 12.57% to $135.0 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Assets Average are $135.0 million (Q1 2025), $154.4 million (Q4 2024), and $172.0 million (Q3 2024).